NCT07084259 (HANYANG-PICK) is a Phase 4 clinical trial of PCSK9 inhibitor in Coronary Artery Disease, sponsored by Hanyang University Seoul Hospital.

Who is sponsoring NCT07084259?

NCT07084259 is sponsored by Hanyang University Seoul Hospital.

What drugs are being tested in NCT07084259?

Interventions in NCT07084259: PCSK9 inhibitor, Standard Lipid-Lowering Therapy.

What condition does NCT07084259 study?

NCT07084259 studies Coronary Artery Disease.

Is NCT07084259 still recruiting?

NCT07084259 is currently not yet recruiting. Last updated 16 July 2025.

Last reviewed 2025-07-16 · How we verify

NCT07084259: HANYANG-PICK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HArnessing Near-infrared Spectroscopy Intravascular Ultrasound Imaging for Yielding Advanced Guidance - PCSK9i for Improving Cardiovascular Outcome in High-Risk Patients

Not yet recruiting Phase 4 Last updated 16 July 2025

What this trial tests

Phase 4 trial testing PCSK9 inhibitor in Coronary Artery Disease in 352 participants. Not yet recruiting.

Timeline

1 July 2025

Primary endpoint
1 June 2030

1 July 2030

Quick facts

Lead sponsor	Hanyang University Seoul Hospital
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	352
Start date	1 July 2025
Primary completion	1 June 2030
Estimated completion	1 July 2030

Drugs / interventions tested

PCSK9 inhibitor — full drug profile →
Standard Lipid-Lowering Therapy — full drug profile →

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Hanyang University Seoul Hospital

Who can join

19 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Patient-oriented Composite Outcome (MACE)
Time frame: 12 months
Composite of all-cause mortality, any myocardial infarction, any stroke, or any clinically driven revascularization.

Sponsor's own description

This pilot study aims to evaluate whether a single dose of PCSK9 inhibitor administered after percutaneous coronary intervention (PCI) can improve long-term cardiovascular outcomes in patients with high post-PCI lipid core burden, as assessed by NIRS-IVUS. The study will assess major adverse cardiovascular events (MACE) over a 12-month follow-up period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Proactive, short-term PCSK9 inhibition after PCI in patients with coronary artery disease at high residual risk: rationale and design of the randomized HANYANG-PICK trial.
Kim W, Park S, Shin JH, Kook H, et al · · 2026 · PMID 41847515 · DOI 10.3389/fcvm.2026.1761093

Verify or expand the search:

Other trials of PCSK9 inhibitor

Trials testing the same drug.

NCT07174375 — PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy · Phase 2, PHASE3 · not yet recruiting
NCT06854523 — Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI) · NA · not yet recruiting
NCT06730802 — Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery · NA · not yet recruiting
NCT06738758 — Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of · recruiting
NCT06520904 — Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography · Phase 4 · recruiting

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Hanyang University Seoul Hospital trials

Trials by the same sponsor.

NCT06144021 — Efficacy and Safety of Kefir Whey Postbiotics · NA · recruiting
NCT06429644 — Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations · completed
NCT05164198 — REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) · Phase 4 · unknown
NCT04871945 — Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis · completed
NCT04567134 — Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07084259 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hanyang University Seoul Hospital
Last refreshed: 16 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07084259.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing